Celcuity's Engagement at Stifel 2025 Healthcare Conference
Celcuity Inc. (Nasdaq: CELC), a forward-looking biotechnology enterprise, has confirmed its participation in the notable Stifel 2025 Healthcare Conference, where groundbreaking advancements in oncology therapies will take center stage. This conference is set to occur in New York, providing an opportunity for leaders within the healthcare sector to converge and discuss innovations and industry developments.
Key Presentation Details
Brian Sullivan, the dynamic Chief Executive Officer and Co-founder of Celcuity, is slated to engage in a fireside chat scheduled for 10:00 a.m. ET on the conference's opening day. His session promises to be insightful as he shares the company's vision and ongoing clinical initiatives. Furthermore, attendees and interested parties will have access to a live webcast of the event, allowing for wider participation beyond the physical venue. This webcast will be available on their official website shortly after the event takes place.
Webcast Information
Those wishing to tune in can easily access the live streaming through the dedicated web link provided by Celcuity. Participants are encouraged to explore the Investors section of the company's website where a replay of the discussion will be available for later viewing. This initiative underscores Celcuity's commitment to transparency and engagement with its stakeholders.
About Celcuity
Celcuity is making significant strides in the biotechnology realm, primarily focusing on the development of targeted therapies for multiple solid tumor types. The cornerstone of their effort is gedatolisib, a cutting-edge therapeutic candidate recognized for its ability to inhibit key pathways associated with cancer progression. Notably, gedatolisib serves as a dual inhibitor of both pan-PI3K and mTORC1/2, offering a comprehensive approach to blocking the PI3K/AKT/mTOR pathway.
Current Clinical Trials and Innovations
Celcuity's clinical endeavors are highlighted by the ongoing Phase 3 trials, VIKTORIA-1 and VIKTORIA-2. These trials are pivotal in evaluating gedatolisib in various combinations, including its usage alongside fulvestrant and CDK4/6 inhibitors. The completion of enrollment in the VIKTORIA-1 trial represents a key milestone in a quest to enhance treatment options for patients battling HR+/HER2- ABC. Additionally, early-stage studies investigating gedatolisib in conjunction with darolutamide for prostate cancer showcase the company's diverse therapeutic landscape.
Strategic Insights and Future Aspirations
Looking ahead, Celcuity is focused on expanding its clinical trial portfolio and enhancing the infrastructure necessary for developing promising oncology interventions. The results from ongoing trials are anticipated to provide valuable insights into the efficacy of their investigational therapies, further informing their strategic positioning within the biotechnology industry.
Connecting with Celcuity
For further information about Celcuity and its innovative approaches to oncology treatment, the company invites interested stakeholders to visit its official website. Here, detailed updates on its pipeline, clinical trials, and company news can be found.
Frequently Asked Questions
What is Celcuity focused on?
Celcuity is a biotechnology company dedicated to developing targeted therapies for oncology, particularly solid tumors.
When will the Stifel 2025 Healthcare Conference take place?
The conference is scheduled for November 11-13, 2025, in New York.
Who will be presenting at the conference?
Brian Sullivan, CEO and Co-founder of Celcuity, will represent the company during a fireside chat session.
How can I access the conference presentation?
The presentation will be streamed live, and a replay will be available on Celcuity's website shortly after the event.
What is gedatolisib?
Gedatolisib is Celcuity's lead therapeutic candidate, a pan-PI3K and mTORC1/2 inhibitor designed to treat various cancer types.
